已收盘 07-02 16:00:00 美东时间
+0.520
+3.21%
An update from Viatris ( ($VTRS) ) is now available. On July 1, 2026, Viatris I...
07-02 05:10
Viatris schedules second-quarter 2026 earnings report and conference call Viatris schedules second-quarter 2026 results for Aug. 6, 2026. Conference call, live webcast set for Aug. 6, 2026 at 8:30 a.m. ET via investor.viatris.com . Disclaimer: This news brief was created by Public Technologies (PUBT
07-01 18:59
Zymeworks Inc. announced its definitive agreement to acquire Theravance Biopharma, Inc. for $17 per share, totaling approximately $929 million. The acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for COPD, to Zymeworks' portfolio. YUPELRI® generated $266.6 million in U.S. net sales in 2025, with 12% growth over 2024, and $62.4 million in Q1 2026, a 7% increase. The transactio...
06-29 10:00
Pfizer dismissed from US states' drug price-fixing lawsuit No proof of Pfizer's direct conspiracy to fix prices 45 U.S. states, others sued over 80 generic drugs States unavailable to comment By Jonathan Stempel June 24 (Reuters) - Pfizer PFE.N has been dismissed as a defendant in a sweeping antitru
06-24 22:48
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds AbbVie deal June 22 (Reuters) - AbbVie ABBV.N has agreed to buy biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. The move adds to a gr
06-22 19:46
SpaceX涨2.52%;Viatris, Inc.涨2.21%;DigitalOcean Holdings涨2.05%
06-16 06:10
An announcement from Viatris ( ($VTRS) ) is now available. On June 12, 2026, Vi...
06-16 06:03
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds GSK deal June 9 (Reuters) - GSK GSK.L has agreed to buy cancer drug developer Nuvalent NUVL.O for $10.6 billion in its biggest deal in years, as the British drugmaker looks to bolster its pipeline and support long-ter
06-09 17:13
Large-cap stocks with low forward price-to-earnings ratios often attract investors searching for companies that may be trading at relatively inexpensive earnings multiples despite maintaining strong u...
05-18 20:13
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a
05-18 20:08